In patients with COVID-19, elevated levels of IL-6 are associated with high levels of lipid peroxidation (33); since HDL-C is eminently prone to oxidative changes (33), sustained elevation of plasma IL-6 resulting from IL-6R blockade may account for the reduced impact of sarilumab on HDL-C levels compared to LDL-C levels. The gene discussed is IL6; the disease is COVID-19.